AI-powered brain tumor analysis

Advanced MRI-based glioma analysis for clinicians and researchers

Start analysis

Solutions

Explore our AI-powered services for glioma analysis

Anatomical Segmentation Service

MRI preprocessing in combination with automated segmentation of enhancing tumor, necrotic core and edema based on Convolutional Neural Networks.

Vascular Heterogeneity Assessment Service

Delineation of functional habitats within the glioblastoma that describe the biomarker heterogeneity of the tumor. Includes all the modules of the Anatomical service

Non-Contrast-Enhancing Tumor Segmentation Service

Automated segmentation of nCET regions using T2 and FLAIR MRI sequences.

Learn more

ONCOhabitats is a software for the evaluation of the heterogeneity of high-grade gliomas (IDH-wild Glioblastoma and IDH-mutant Astrocytoma) using MRI data. The system offers two services: 1) segmentation of high-grade gliomas and 2) delineation of vascular heterogeneity of high-grade gliomas using the HTS method.

At ONCOhabitats we want to help health professionals, researchers and companies to discover the true potential of artificial intelligence. Our services have been retrospectively evaluated in hospitals in Spain, Italy, Belgium and Norway in the  NCT03439332 Clinical Study. Alvarez-Torres, Maria del Mar. et al. (2020) ‘Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study’, Journal of Magnetic Resonance Imaging, 51(5), pp. 1478–1486. Available at: https://doi.org/10.1002/jmri.26958 .

ONCOhabitats has been carried out within the ALBATROSS (PID2019-104978RB-I00) and SINUE (INNEST/2022/87) projects, and is patented in Spain (patent number ES201431289A), Europe (EP3190542A1) and the United States (US20170287133A1).  

The software was published on this website for academic purposes on May 3, 2021. Currently, ONCOhabitats is being validadated by the clinical study “Evaluación de la viabilidad de ONCOhabitats para ayudar a la planificación de la cirugía y el tratamiento en pacientes con Glioblastoma, tipo IDH-wild (INNEST/2022/87)”. This clinical validation has been funded by ALBATROSS project (PID2019-104978RB-100 – Agencia Estatal de Investigación) and SINUÉ project (INNEST/2022/87 – Agencia Valenciana de la Innovación).

As dictated in Chapter III of Annex I of Regulation 2017-745 (page 103), which is available at the following link: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745#page=103 , the instructions for use and labeling are elaborated and the application of the regulation is justified here .

Contact

For inquiries, collaborations or support:

info@oncohabitats.upv.es